ClinicalTrials.gg
RecruitingNCT06467292Updated Aug 18, 2026

Speech Motor Learning and Retention (Master Protocol)

An interventional study of continuous theta-burst stimulation (cTBS) and Adaptation in Speech, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Yale University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well.

Read the detailed description

Aim 1 involves tests of speech motor memory retention following disruption of left hemisphere brain activity in either auditory, somatosensory or motor cortex or to a control site (hand area motor cortex right hemisphere). Continuous theta-burst stimulation (cTBS) is delivered following adaptation to altered auditory feedback to assess its effects on the retention of new learning.

Aim 2 assesses the temporal order in which plasticity occurs in cortical motor and sensory brain areas during speech motor learning.

In Aim 3, resting-state fMRI will be interleaved with speech motor adaptation. For information specific to each aim, please refer to the below corresponding, separate, clinicaltrials.gov records: unique IDs: 2000037622_a for Aim 1, 2000037622_b for Aim 2 and 2000037622_c for Aim 3.

02

Conditions studied

  • Speech

Browse trials for

Keywords

  • Speech Motor Learning
  • Retention
03

In context

Speech

205 studies on the registry are indexed under Speech; 80 are open to participants now.

This study's planned enrollment of 330 is above the median of 52 across 141 interventional studies indexed under Speech.

Browse Speech studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fluent English speakers
  • Right-handed
  • Normal hearing
  • No speech disorder or reading disability

Exclusion criteria

Exclusion Criteria:

  • Cardiac pacemaker
  • Aneurysm clip
  • Heart or Vascular clip
  • Prosthetic valve
  • Metal implants
  • Metal in brain, skull, or spinal cord
  • Implanted neurostimulator
  • Medication infusion device
  • Cochlear implant or tinnitus (ringing in ears)
  • Personal and/or family history of epilepsy or other neurological disorders or history of head concussion
  • Psychoactive medications
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Speech Motor Learning and Retention Aim 1

    Aim 1: Participants will perform learning tasks while receiving altered/unaltered auditory feedback with cTBS applied to the appropriate area of the brain following learning. Retention of learning is assessed 24 hours later.

    Device: continuous theta-burst stimulation (cTBS) · Behavioral: Adaptation

  • Experimental
    Speech Motor Learning and Retention Aim 2

    Aim 2: Participants will perform learning tasks combined with shifted auditory feedback. Motor cortical excitability will be measured using single-pulse TMS to elicit motor evoked potentials.

    Behavioral: Adaptation · Device: Single pulse Transcranial magnetic stimulation (TMS)

  • Experimental
    Speech Motor Learning and Retention Aim 3

    Aim 3: Participants will have fMRI with behavioral measures of speech motor learning.

    Behavioral: Adaptation · Device: fMRI

Interventions

  • Devicecontinuous theta-burst stimulation (cTBS)

    cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.

  • BehavioralAdaptation

    Auditory adaptation in speech

  • DeviceSingle pulse Transcranial magnetic stimulation (TMS)

    TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.

  • DevicefMRI

    To assess functional connectivity patterns between regions that predict learning.

06

What researchers measure

Primary outcomes

  1. Speech motor learning

    Audapter software will be used to alter the first and second formant frequencies of the spoken words and this is played back to subjects through headphones. Subjects will be tested both with unaltered feedback and with abruptly introduced frequency shifts.The change in the first (F1) and second format frequency (F2) values will be assessed using Praat.

    Time frame: Performance as measured at the end of learning (30 minute session)

  2. Retention of learning

    The retention of adaptation to altered auditory feedback (and relearning) will be quantified in terms of F1 and F2 frequency shifts (relative to pre-training baseline). Larger values indicate more complete relearning or retention.

    Time frame: 24 hours after learning (re-test lasts 30 minutes)

07

Study locations

1 of 1 sites recruiting
  • Yale Child Study Center
    New Haven, Connecticut 06520, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.

Of 85 non-industry interventional studies with no phase under Speech, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 65. This study's planned 49 months is close to that.

Counting every sponsor, half of 90 studies reached it within 45 months; a quarter within 15 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 21, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Nov 30, 2028
CompletionEst.
May 31, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467292
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Oct 1, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Michael Stern
Contact
michael.stern@yale.edu
2038656163
David Ostry
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion